Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3748
Name esophagus squamous cell carcinoma
Definition An esophageal carcinoma that derives_from epithelial squamous cells located_in the esophagus.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer esophageal cancer esophageal carcinoma esophagus squamous cell carcinoma


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA E545K LY294002 esophagus squamous cell carcinoma sensitive detail...
TP53 mutant Adavosertib + Radiotherapy esophagus squamous cell carcinoma sensitive detail...
TP53 mutant Adavosertib esophagus squamous cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting USA | ITA | FRA | ESP | DEU | CAN 1
NCT01490749 Phase I Carboplatin + Cetuximab + Everolimus + Paclitaxel Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer Completed USA 0
NCT01822613 Phase Ib/II Docetaxel + Irinotecan + Paclitaxel Alpelisib + Elgemtumab Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) Completed USA | ESP | CAN | BEL 5
NCT02013154 Phase I DKN-01 + Paclitaxel A Study of DKN-01 in Combination With Paclitaxel Completed USA 0
NCT02389751 Phase I Carboplatin Paclitaxel Ganetespib A Study of Ganetespib in Combination With Chemoradiation Completed USA 0
NCT02559687 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) Completed 0
NCT02564263 Phase III Pembrolizumab Docetaxel + Irinotecan + Paclitaxel Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Completed 0
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Active, not recruiting USA 0
NCT02971956 Phase II Pembrolizumab A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer Active, not recruiting USA 0
NCT03096054 Phase I LY3143921 A CR-UK Phase I Trial of LY3143921 Active, not recruiting 1
NCT03132922 Phase I ADP-A2M4 cells MAGE-A4c1032T for Multi-Tumor Active, not recruiting USA | CAN 0
NCT03143153 Phase III Ipilimumab + Nivolumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Nivolumab A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) Active, not recruiting USA | ITA | FRA | ESP | CAN | AUT 21
NCT03165994 Phase II APX005M + Carboplatin + Paclitaxel APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers Active, not recruiting USA 0
NCT03189719 Phase III Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Pembrolizumab First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) Active, not recruiting USA | FRA | ESP | DEU | CAN 21
NCT03212469 Phase Ib/II Durvalumab + Tremelimumab A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE) Recruiting FRA 0
NCT03261947 Phase II Simurosertib A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Completed USA 1
NCT03339843 Phase II Abemaciclib Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) Active, not recruiting FRA | BEL 0
NCT03430843 Phase III Docetaxel Paclitaxel Tislelizumab Irinotecan A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL 5
NCT03437200 Phase II Nivolumab Ipilimumab + Nivolumab Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL) Unknown status FRA | ESP 0
NCT03486730 Phase Ib/II BT1718 BT1718 in Patients With Advanced Solid Tumours. Recruiting 1
NCT03610711 Phase Ib/II Nivolumab + Relatlimab Nivolumab REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION) Recruiting USA 0
NCT03694249 Phase II Ifetroban sodium Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence Recruiting USA 0
NCT03748134 Phase III Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Sintilimab Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Sintilimab Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma (ORIENT-15) Recruiting USA | FRA | ESP | BEL 3
NCT03777813 Phase II Fluorouracil + Leucovorin + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer (ARION) Recruiting FRA 0
NCT03783442 Phase III Cisplatin Paclitaxel Tislelizumab Oxaliplatin Fluorouracil Capecitabine A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL 10
NCT04000529 Phase I Spartalizumab + TNO155 Ribociclib + TNO155 Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies Recruiting USA | ESP | DEU | BEL 5
NCT04032704 Phase II Ladiratuzumab vedotin A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Recruiting USA | ITA 4
NCT04047862 Phase I BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors Recruiting USA 5
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Terminated USA 1
NCT04140500 Phase I RO7247669 Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors Recruiting USA | ESP 6
NCT04145622 Phase Ib/II DS-7300a Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting USA 1
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting USA 4
NCT04460937 Phase I Adavosertib Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Suspended USA 0
NCT04543617 Phase III Atezolizumab Atezolizumab + Tiragolumab A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (SKYSCRAPER-07) Recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 23
NCT04550260 Phase III Cisplatin + Fluorouracil Capecitabine + Cisplatin Capecitabine + Cisplatin + Durvalumab Cisplatin + Durvalumab + Fluorouracil Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (KUNLUN) Recruiting USA | FRA | ESP | CAN | BEL 13
NCT04695847 Phase I M1231 M1231 in Participants With Solid Tumors Recruiting USA | CAN 0
NCT04704154 Phase II Nivolumab + Regorafenib A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors Active, not recruiting USA | ITA | FRA | BEL 4
NCT04713891 Phase I KF-0210 Atezolizumab + KF-0210 A Study of KF-0210 in Advanced Solid Tumors Patients Recruiting 1
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04732494 Phase II BGBA1217 + Tislelizumab Tislelizumab AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Recruiting FRA | ESP 4
NCT04785820 Phase II RO7121661 Nivolumab RO7247669 A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus Recruiting ITA | FRA | ESP | DEU | BEL 16
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Recruiting USA 0
NCT04929392 Phase II Carboplatin + Lenvatinib + Paclitaxel + Pembrolizumab Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer Recruiting USA 0
NCT04939701 Phase Ib/II ASP0739 + Pembrolizumab ASP0739 Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants Recruiting USA 0
NCT04949256 Phase III Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + Lenvatinib + Pembrolizumab Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) Recruiting USA | ITA | FRA | ESP 15
NCT04958239 Phase I BI 765179 + Ezabenlimab BI 765179 A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Recruiting USA | ESP | BEL 2
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) Recruiting USA | ITA | FRA | ESP | DEU | CAN 9
NCT05101070 Phase Ib/II Pembrolizumab + S-531011 Pembrolizumab S-531011 S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) Recruiting USA 1
NCT05104567 Phase II Cetuximab + THOR-707 Pembrolizumab + THOR-707 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL 5
NCT05144698 Phase II RAPA-201 RAPA-201 Therapy of Solid Tumors Recruiting USA 0
NCT05187182 Phase I CA-4948 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin CA-4948 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer Not yet recruiting USA 0
NCT05208762 Phase I SGN-PDL1V A Study of SGN-PDL1V in Advanced Solid Tumors Recruiting USA | CAN 0
NCT05221320 Phase II Hydroxychloroquine + Ulixertinib Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Recruiting USA 0
NCT05245760 Phase II Tislelizumab ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer (CRATER) Withdrawn USA 0
NCT05325866 Phase I Bemarituzumab A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) Recruiting USA | FRA | ESP | CAN | BEL | AUT 10
NCT05342636 Phase Ib/II Irinotecan + Pembrolizumab Irinotecan + MK-4830 + Pembrolizumab MK-4830 + Paclitaxel + Pembrolizumab Lenvatinib + MK-4830 + Pembrolizumab Irinotecan + MK-4280A MK-4280A + Paclitaxel Paclitaxel + Pembrolizumab A Study of Combination Therapies With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer (MK-3475-06A) Recruiting ITA 3
NCT05584709 Phase I STI-6129 Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors Not yet recruiting USA 0